|
My 16 year old daughter has APL (diagnosed 2/02) and is taking ATRA. I want to know from others how they are tolerating ATRA. She has terrible headaches and irritability. Have people found any ways to make the ATRA have less side effect? ... cancer.org...
|
csn.cancer.org/node/138628
csn.cancer.org/node/138628
|
|
|
|
The APL model, therefore, provides a striking example of oncogene-targeted cancer therapies. In contrast to the rational design of kinase inhibitors, therapeutic use of ATRA and arsenic in APL were found largely by chance.
|
www.nature.com/onc/journal/v20/n49/full/1204851a.html
|
|
|
Both CORE resources are designed to help clarify the issues and facilitate the processes involved when submitting reimbursement claims for Cephalon Oncology products like TRISENOX® (arsenic trioxide) injection, a treatment option for APL patients whose cancer returns or does not respond to initial therapy.
|
www.trisenox.com/patient/216-APL-Life.aspx
www.trisenox.com/patient/216-APL-Life.aspx
|
|
Questions about cancer?; ... 1-800-4-CANCER; ... National Cancer Institute...
|
www.cancer.gov/dictionary/?CdrID=522912
www.cancer.gov/dictionary/?CdrID=522912
|
|
Acute promyelocytic leukemia (APL) is associated with chromosomal translocations that always involve the gene, which variably fuses to one of several distinct loci, including or ( genes). Due to the reciprocity of the translocation, ... Reciprocal products of chromosomal translocations in human cancer pathogenesis:
|
www.cell.com/cancer-cell/abstract/S1535-6108(08)00413-3
www.cell.com/cancer-cell/abstract/S1535-6108(08)00413-3
|
|
Correspondence from The New England Journal of Medicine -- APL during Gefitinib Treatment for Non-Small-Cell Lung Cancer ... Table 1. Characteristics of Three Patients with APL during Treatment with Gefitinib for Recurrence of Non–Small-Cell Lung Cancer.
|
content.nejm.org/cgi/content/full/352/8/843
|
|
It can also be used in a person with APL whose cancer has come back or does not respond to the ATRA and chemotherapy treatment. ... For more information about APL or any cancer concern, contact the Holden Comprehensive Cancer Center/Cancer Information Service.
|
www.uihealthcare.com/depts/cancercenter/patienteducatio...
www.uihealthcare.com/depts/cancercenter/patienteducation/leukemiahodgkins.html
|
|
Twenty-eight (70%) of the 40 patients treated at nine US cancer centers in the phase II trial had complete remissions, according to Cell Therapeutics. The median time to remission was 51 days. Of the patients achieving a complete remission, 86% also had clearing of the chromosomal abnormality associated with APL.
|
cancernetwork.com/oni/showArticle.jhtml?articleId=17910...
cancernetwork.com/oni/showArticle.jhtml?articleId=179102931
|
|
Cancer to be world's top killer by 2010, WHO says ... Fwd: NovaRx begins phase III trial for lung cancer... ... Fwd: Hot dogs cast as villain in cancer group's ad...
|
toppikscaplcancer.blogspot.com/2008/06/fwd-photo-by-bla...
toppikscaplcancer.blogspot.com/2008/06/fwd-photo-by-blaise-kielar-raleigh-news.html
|
|
